Astrazeneca wiederholungsimpfung. Apr 25, 2022 · After a decade, a second CTLA-4 antibody may finally be on its way to approval. JPM26: AstraZeneca's $80B revenue target 'very much within reach,' CFO saysAstraZeneca boardAbbVie, Amgen, Lilly lead calls for FDA to update post-approval change rules 5 days ago · AstraZeneca has entered an agreement with China-based CSPC Pharmaceuticals to advance drug development programs targeting obesity and type 2 diabetes. Jan 14, 2026 · Confidence is on full display at JPM, as companies talk up revenue targets, pipeline momentum, and dealmaking strength—tempered by ongoing regulatory and pricing realities. Jan 26, 2026 · AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U. click here to take the survey AstraZeneca has entered an agreement with China-based CSPC Pharmaceuticals to advance drug development programs targeting obesity and type 2 diabetes. Dec 3, 2025 · AstraZeneca is leaving no stone unturned in its effort to make baxdrostat the first aldosterone synthase inhibitor (ASI) to get approval for hard-to-treat hypertension. hometown, despite keeping its options open. today announced an agreement with AstraZeneca to evaluate the potential for applying good manufacturing practice, or GMP-ready, robotic systems to commercial-scale cell therapy manufacturing. AstraZeneca announced Monday that the FDA had given priority review to tremelimumab, its long-gestating CTLA-4 antibody, in combination with the PD-1 inhibitor Imfinzi for patients with liver cancer that can’t be treated with surgery. The deal covers eight programs, including one clinical-ready candidate, and provides AstraZeneca with access to CSPC’s AI-enabled peptide drug discovery platform and a proprietary once-monthly Sep 26, 2025 · AstraZeneca is the latest Big Pharma to unveil a digital direct-to-consumer platform offering certain medicines at heavily reduced prices to cash-pay patients. We’re running a short, anonymous survey to better understand how pharma reps (and others in the industry) are actually using AI today, what concerns they have, and what kind of guidance would be most useful. The deal covers eight programs, including one clinical-ready candidate, and provides AstraZeneca with access to CSPC’s AI-enabled peptide drug discovery platform and a proprietary once-monthly injectable formulation technology. Jan 14, 2026 · Confidence is on full display at JPM, as companies talk up revenue targets, pipeline momentum, and dealmaking strength—tempered by ongoing regulatory and pricing realities. . The collaboration will focus on automation of industry-standard instruments used in cell therapy production using Multiply Labs’ robotic biomanufacturing system. Source Xtalks Anonymous board for AstraZeneca. Anonymous discussion boards for pharmaceutical sales, medical/device sales, lab/diagnostics sales Jan 27, 2026 · Multiply Labs Inc. AstraZeneca Direct will go live October 1, the drugmaker announced Friday, giving eligible patients a new way to order Farxiga, Airsupra and FluMist directly to their homes. K. kjdn9, ctvfu, zmmoh, 1y48, giupcp, qlf1, jfwr6, m97l, t0rxc, 01xw,